Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Director Sells $6,581,223.04 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 309,268 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $21.28, for a total value of $6,581,223.04. Following the completion of the transaction, the director directly owned 1,016,633 shares in the company, valued at $21,633,950.24. This represents a 23.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Stock Performance

NASDAQ DYN opened at $23.07 on Friday. Dyne Therapeutics, Inc. has a fifty-two week low of $8.06 and a fifty-two week high of $25.00. The firm has a market capitalization of $3.81 billion, a P/E ratio of -7.16 and a beta of 1.06. The stock has a 50-day simple moving average of $18.63 and a two-hundred day simple moving average of $18.16. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same period in the previous year, the company posted ($1.05) EPS. On average, equities analysts forecast that Dyne Therapeutics, Inc. will post -3.02 earnings per share for the current year.

Institutional Investors Weigh In On Dyne Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Hilton Head Capital Partners LLC acquired a new stake in shares of Dyne Therapeutics in the first quarter valued at approximately $26,000. Strs Ohio acquired a new position in shares of Dyne Therapeutics during the 4th quarter valued at about $51,000. Aster Capital Management DIFC Ltd purchased a new position in Dyne Therapeutics during the fourth quarter worth approximately $84,000. Steward Partners Investment Advisory LLC raised its position in shares of Dyne Therapeutics by 102.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after buying an additional 2,465 shares during the period. Finally, Tower Research Capital LLC TRC raised its position in shares of Dyne Therapeutics by 275.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after buying an additional 7,697 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

Wall Street Analysts Forecast Growth

DYN has been the topic of several research analyst reports. Wall Street Zen upgraded shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Evercore set a $33.00 price objective on shares of Dyne Therapeutics in a research report on Friday, May 15th. Chardan Capital reissued a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 9th. Finally, TD Cowen started coverage on shares of Dyne Therapeutics in a research note on Friday, June 26th. They set a “buy” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $34.17.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.